Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
In a one-year study, patients taking the lowest starter doses of GLP-1 weight-loss drugs lost 5.5% of body weight with Eli Lilly’s tirzepatide and 2.2% with Novo Nordisk’s semaglutide, along with less nausea at the lower doses.
Sep 17, 2026 ·
Yahoo Finance

















